Epitherapeutics raises DKK 10 M in an extended seed financing, LFI Life Science Investment joins Syndicate; LFI's Mette Kirstine Agger joins Board

Copenhagen, Denmark, February 5, 2010

Epitherapeutics, a biopharmaceutical company making innovative pharmaceutical agents based on its discoveries and leading scientific position in the field of epigenetics, announced today the participation of Life Science Investments (the venture arm of the Lundbeck Foundation/LFI) in its seed round, bringing the total seed financing to DKK 34 M. LFI Life Science Investments joins an investor group that includes Novo Seeds and Seed Capital. Coincident with the extension of the seed round, Mette Kirstine Agger, Executive Director and Head of LFI Life Science Investments, joins the Company's Board of Directors.

Click here to read Epitherapeutics' press release.